Hua-Li Wang, Xue Ma, Xin-Yuan Guan, Chen Song, Guo-Bo Li, Ya-Mei Yu, & Ling-Ling Yang. (2022). Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib. Elsevier.
Chicago Style (17th ed.) CitationHua-Li Wang, Xue Ma, Xin-Yuan Guan, Chen Song, Guo-Bo Li, Ya-Mei Yu, and Ling-Ling Yang. Potential Synthetic Lethality for Breast Cancer: A Selective Sirtuin 2 Inhibitor Combined with a Multiple Kinase Inhibitor Sorafenib. Elsevier, 2022.
MLA (9th ed.) CitationHua-Li Wang, et al. Potential Synthetic Lethality for Breast Cancer: A Selective Sirtuin 2 Inhibitor Combined with a Multiple Kinase Inhibitor Sorafenib. Elsevier, 2022.
Warning: These citations may not always be 100% accurate.